Aurinia to acquire Kezar for $6.955/share plus CVR; tender offer by April 13

Aurinia Pharmaceuticals Inc.

Aurinia (AUPH) to acquire Kezar (KZR) for $6.955 per share in cash plus one non-transferable CVR.
CVR entitles holders to potential payments from zetomipzomib milestones, Everest/Enodia proceeds, and Kezar's net cash over $50M.
Kezar's lead asset zetomipzomib is a first-in-class immunoproteasome inhibitor for autoimmune hepatitis and lupus.
Tang Capital Partners (9% holder) signed support agreement to tender shares; deal expected to close Q2 2026.
Kezar's board unanimously approved; TD Cowen and Cooley advised Kezar.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aurinia Pharmaceuticals Inc. entered into Agreement and Plan of Merger with Kezar Life Sciences, Inc. (effective 2026-03-30).

Action: entry
Agreement: merger
Counterparty: Kezar Life Sciences, Inc.
Effective: 2026-03-30

Exact text from the filing

On March 30, 2026, Aurinia Pharma U.S., Inc., a Delaware corporation (“Parent”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Kezar Life Sciences, Inc., a Delaware corporation (the “Company” or “Kezar”), Parent, Aurinia Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub” and together with Parent, the “Buyer Entities”)

View on SEC.gov

Browse all material agreements →

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001600620-26-000035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.